Gastrointestinal Stromal Tumor Clinical Trials

127 clinical trials for Gastrointestinal Stromal Tumor across international registries, including 17 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis — RECRUITING
• LRG GIST Patient Registry — RECRUITING
• Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients — RECRUITING · NA
• PH 2 Pemigatinib in SDH-deficient GIST — RECRUITING · PHASE2
• Mesenteric Vascular Preconditioning Combined With Laparoscopic and Endoscopic Cooperative Surgery for Submucosal Tumor at the Gastroesophageal Junction — RECRUITING · PHASE2
• A Study of HQP1351 in Patients With GIST or Other Solid Tumors — RECRUITING · PHASE1
• A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) — RECRUITING · PHASE1
• A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST) — RECRUITING · PHASE1
• Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma — RECRUITING
• A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY OF IDRX-42 (GSK6042981) VERSUS SUNITINIB IN PARTICIPANTS WITH METASTATIC AND/OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMORS (GIST) AFTER IMATINIB THERAPY (STRATEGIST 3) — RECRUITING · PHASE3
• Multicenter Observational Study of Multimodal AI for Upper GI Mesenchymal Tumor Diagnosis — RECRUITING
• An International Study on Pediatric Patients With Rare Tumors. — RECRUITING
• AN INTERNATIONAL, PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY OF RIPRETINIB VS SUNITINIB IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR (GIST) WITH KIT EXON 11 AND CO-OCCURRING KIT EXONS 17 AND/OR 18 MUTATIONS WHO WERE PREVIOUSLY TREATED WITH IMATINIB (INSIGHT) — RECRUITING · PHASE3
• (PEAK) A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER CLINICAL STUDY OF CGT9486+SUNITINIB VS SUNITINIB IN SUBJECTS WITH LOCALLY ADVANCED, UNRESECTABLE, OR METASTATIC GASTROINTESTINAL STROMAL TUMORS — RECRUITING · PHASE3
• Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors — RECRUITING · PHASE2
• A PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BELZUTIFAN (MK-6482, FORMERLY PT2977) MONOTHERAPY IN PARTICIPANTS WITH ADVANCED PHEOCHROMOCYTOMA/PARAGANGLIOMA (PPGL), PANCREATIC NEUROENDOCRINE TUMOR (PNET), VON HIPPEL-LINDAU (VHL) DISEASE-ASSOCIATED TUMORS, ADVANCED GASTROINTESTINAL STROMAL TUMOR (WT GIST), OR ADVANCED SOLID TUMORS WITH HIF-2A RELATED GENETIC ALTERATIONS — RECRUITING · PHASE2
• A PHASE 3, INTERVENTIONAL, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY OF DCC-2618 VS SUNITINIB IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS AFTER TREATMENT WITH IMATINIB — RECRUITING · PHASE3
• Hyperpolarized MRI for GIST on Imatinib — NOT_YET_RECRUITING
• Oncogenetic Panel and Integrated Clinical Data Registry Study for Wild Type Gastrointestinal Stromal Tumor Patients — ACTIVE_NOT_RECRUITING
• First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• Nivolumab and Ipilimumab in Treating Patients With Rare Tumors — ACTIVE_NOT_RECRUITING · PHASE2
• A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY OF VELZATINIB (GSK6042981) VERSUS IMATINIB IN PARTICIPANTS WITH PREVIOUSLY UNTREATED METASTATIC AND/OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMORS (GIST) — NOT_YET_RECRUITING · PHASE3
• Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate — ACTIVE_NOT_RECRUITING · PHASE2
• A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib — COMPLETED · PHASE2
• Three versus five years of adjuvant imatinib as treatment of patients with operable GIST with a high risk for recurrence: A randomised phase III study. — TERMINATED · PHASE3
• MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) — ACTIVE_NOT_RECRUITING · PHASE1
• Resistance Profiling Using Functional Imaging and Next Generation Sequencing in Refractory Gastrointestinal Stomal Tumors (GIST) — NOT_YET_RECRUITING
• CEH-EUS for Differentiating GISTs and Leiomyomas: A Multicenter Prospective Self-Controlled Study — NOT_YET_RECRUITING
• Expanded Access to Everolimus, for an Individual Patient With GIST (Gastrointestinal Stromal Tumors)(CTMS#18-0019) — TERMINATED
• Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma — COMPLETED · PHASE2
• A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST — COMPLETED · PHASE2
• Efficacy of adjuvant Imatinib in patients with intermediate-risk gastrointestinal stromal tumor with a high-risk Genomic Grade Index. Multicenter, prospective, randomized study. — TERMINATED · PHASE3
• Advanced Gastrointestinal Endoscopic Imaging — TERMINATED · NA
• Long Term Effects of Tyrosine Kinase Inhibitor Therapy on Ovarian Reserve and Fertility in Patients With Chronic Myeloid Leukemia or Gastrointestinal Stromal Tumor — WITHDRAWN
• Endoscopic Ultrasound Radiofrequency Ablation for GISTs — OTHER · NA
• Imatinib Mesylate in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor — COMPLETED · PHASE2
• Surgery in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor — COMPLETED · PHASE2
• A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen — COMPLETED · PHASE1
• STUDY OF INAVOLISIB IN A PATIENT WITH REFRACTORY METASTATIC PIK3CA-MUTANT GIST: A PEDIATRIC/YOUNG ADULT ONCOLOGY PRECISION MEDICINE STUDY — COMPLETED
• Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery — COMPLETED · PHASE2
• Ripretinib Combined With Surgery in Advanced GIST That Have Failed Imatinib Therapy: A Multicenter,Observational Study — OTHER
• Unifying Advanced Treatment With Advanced Imaging — COMPLETED
• SSG XXV: The Stop-GIST Trial; Discontinuation of Imatinib in Patients With Oligo-metastatic GIST — SUSPENDED · NA
• A PHASE 1B/2, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, EFFICACY, AND PHARMACOKINETICS OF RIPRETINIB IN COMBINATION WITH BINIMETINIB IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR (GIST) — NOT_YET_RECRUITING · PHASE1
• Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST — COMPLETED · PHASE1
• A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST) — COMPLETED · PHASE1
• Influence of an Acidic Beverage on the Imatinib Exposure After Major Gastrectomy — TERMINATED · PHASE1
• Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor — COMPLETED · PHASE2
• Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor — COMPLETED · PHASE2
• Clinical Outcome of Female Non-gastric Gastrointestinal Stromal Tumor — COMPLETED

Refine this search